Status:
COMPLETED
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
Lead Sponsor:
Centre Leon Berard
Collaborating Sponsors:
UMR-S Inserm 1036
Conditions:
Colorectal Cancer
Metastasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response. Biological factors will be correlate...
Eligibility Criteria
Inclusion
- Patient with a metastatic colorectal cancer proved histologically and treated with bevacizumab in first line.
- At least one extra-osseous, non-irradiated, measurable site (\>= 10 mm with spiral CT).
- No prior radiotherapy treatment unless treatment is over for at least 4 weeks.
- Adult patients.
- PS \<= 2.
- Life expectancy greater than 3 months.
- Mandatory affiliation with a healthy security insurance.
- Signed written informed consent.
Exclusion
- Prior chemotherapy for the metastatic cancer.
- Prior bevacizumab treatment.
- Other current cancer or previous cancer detected in the last 5 years that can be linked to the current disease.
- Patient deprived of freedom.
- Pregnant or lactating women.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01405430
Start Date
May 1 2010
End Date
May 1 2014
Last Update
June 29 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Privé Jean Mermoz
Lyon, France, 69008
2
Centre Léon Bérard
Lyon, France, 69373